Repressive effects of resveratrol on androgen receptor transcriptional activity

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Shi, Wen Feng ^a   Leong, Melanie ^b   Cho, Ellen ^b   Farrell, Joseph ^b   Chen, Han Chun ^c   Tian, Jun ^a   Zhang, Dianzheng ^b,c  

^a SHANDONG UNIVERSITY   (China)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; RESVERATROL; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; STILBENE DERIVATIVE;

ARTICLE; CELL FUNCTION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RNA ISOLATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HELA CELL; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

RICE STRIPE VIRUS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STILBENES; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 70350560541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007398     Document Type: Article

References (51)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. (2005) Cancer statistics. CA Cancer J Clin 55(1): 10-30.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, et al. (2004) Cancer statistics. CA Cancer J Clin 54(1): 8-29.
3. OH WK (2002) Secondary hormonal therapies in the treatment of prostate cancer. Urology 87, 92; discussion 93.
4. Denis LJ, Griffiths K (2000) Endocrine treatment in prostate cancer. Semin Surg Oncol 18(1): 52-74.
5. Bostwick DG (1992) Prostatic intraepithelial neoplasia (PIN): Current concepts. J Cell Biochem Suppl 16H: 10-9.
6. Ratan HL, Steward WP, Gescher AJ, Mellon JK (2002) Resveratrol-a prostate cancer chemopreventive agent? Urol Oncol 7(6): 223-7.
7. Chang CS, Kokontis J, Liao ST (1988) Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240(4850): 324-6.
8. Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C (2005) Inhibition of the akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. Mol Carcinog 44(1): 1-10.
9. Agoulnik IU, Weigel NL (2008) Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol 617: 245-55.
10. Agoulnik IU, Weigel NL (2006) Androgen receptor action in hormonedependent and recurrent prostate cancer. J Cell Biochem 99(2): 362-72.
11. Fletterick RJ (2005) Molecular modelling of the androgen receptor axis: Rational basis for androgen receptor intervention in androgen-independent prostate cancer. BJU Int 96 Suppl 2: 2-9.
12. Kageyama Y, Hyochi N, Kihara K, Sugiyama H (2007) The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer. Recent Patents Anticancer Drug Discov 2(3): 203-11.
13. Yoon HG, Wong J (2005) The corepressors SMRT and N-CoR are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol 20(5): 1048-60.
14. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, et al. (1995) Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and asians in the united states and canada. J Natl Cancer Inst 87(9): 652-61.
15. Thorne J, Campbell MJ (2008) The vitamin D receptor in cancer. Proc Nutr Soc 67(2): 115-27.
16. DePrimo SE, Shinghal R, Vidanes G, Brooks JD (2001) Prevention of prostate cancer. Hematol Oncol Clin North Am 15(3): 445-57.
17. Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman R (2004) Prostate cancer chemoprevention agent development: The national cancer institute, division of cancer prevention portfolio. J Urol 171(2 Pt 2): S68, 74; discussion S75.
18. Signorelli P, Ghidoni R (2005) Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. J Nutr Biochem 16(8): 449-66.
19. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB (2002) An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem 50(3): 431-5.
20. Careri M, Corradini C, Elviri L, Nicoletti I, Zagnoni I (2003) Direct HPLC analysis of quercetin and trans-resveratrol in red wine, grape, and winemaking byproducts. J Agric Food Chem 51(18): 5226-31.
21. Bertelli AA, Giovannini L, Stradi R, Bertelli A, Tillement JP (1996) Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4′,5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int J Tissue React 18(2-3): 67-71.
22. Bertelli AA, Giovannini L, Stradi R, Urien S, Tillement JP (1998) Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp Clin Res 24(1): 51-5.
23. Bertelli AA, Giovannini L, Stradi R, Urien S, Tillement JP (1996) Kinetics of trans- and cis-resveratrol (3,4′,5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res 16(4-5): 77-81.
24. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275(5297): 218-20.
25. Schoonen WM, Salinas CA, Kiemeney LA, Stanford JL (2005) Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer 113(1): 133-40.
26. Hsieh TC, Wu JM (2000) Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res 20(1A): 225-8.
27. Hsieh TC, Wu JM (1999) Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249(1): 109-15.
28. Benitez DA, Pozo-Guisado E, Clementi M, Castellon E, Fernandez-Salguero PM (2007) Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: Modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 96(10): 1595-604.
29. Yuan H, Pan Y, Young CY (2004) Overexpression of c-jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 213(2): 155-63.
30. Mitchell SH, Zhu W, Young CY (1999) Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59(23): 5892-5.
31. Wang TT, Hudson TS, Wang TC, Remsberg CM, Davies NM, et al. (2008) Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 29(10): 2001-10.
32. Jones SB, DePrimo SE, Whitfield ML, Brooks JD (2005) Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 14(3): 596-604.
33. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, et al. (2008) Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 9(1): 7-14.
34. Gao S, Liu GZ, Wang Z (2004) Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 59(2): 214-25.
35. Harada N, Murata Y, Yamaji R, Miura T, Inui H, et al. (2007) Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 53(6): 556-60.
36. Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, et al. (2006) Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A 103(7): 2190-5.
37. Ogryzko VV, Kotani T, Zhang X, Schiltz RL, Howard T, et al. (1998) Histone-like TAFs within the PCAF histone acetylase complex. Cell 94(1): 35-44.
38. Zhang D, Yoon HG, Wong J (2005) JMJD2A is a novel N-CoR-interacting protein and is involved in repression of the human transcription factor achaete scute-like homologue 2 (ASCL2/Hash2). Mol Cell Biol 5(15): 6404-14.
39. Zhang D, Cho E, Wong J (2007) A critical role for the co-repressor N-CoR in erythroid differentiation and heme synthesis. Cell Res 17(9): 804-14.
40. Meeran SM, Katiyar S, Katiyar SK (2008) Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol 229(1): 33-43.
41. Meeran SM, Katiyar SK (2008) Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci 13: 2191-202.
42. Kong AN, Yu R, Hebbar V, Chen C, Owuor E, et al. (2001) Signal transduction events elicited by cancer prevention compounds. Mutat Res 480-481: 231-41.
43. Beck C, Uramoto H, Boren J, Akyurek LM (2004) Tissue-specific targeting for cardiovascular gene transfer. potential vectors and future challenges. Curr Gene Ther 4(4): 457-67.
44. Aziz MH, Nihal M, Fu VX, Jarrard DF, Ahmad N (2006) Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 39-kinase/Akt pathway and bcl-2 family proteins. Mol Cancer Ther 5(5): 1335-41.
45. Scherer WF, Syverton JT, Gey GO (1953) Studies on the propagation in vitro of poliomyelitis viruses. IV. viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 97(5): 695-710.
46. Agoulnik IU, Vaid A, Bingman WE 3rd, Erdeme H, Frolov A, et al. (2005) Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65(17): 7959-67.
47. Shih HM, Chang CC, Kuo HY, Lin DY (2007) Daxx mediates SUMOdependent transcriptional control and subnuclear compartmentalization. Biochem Soc Trans 35(Pt 6): 1397-400.
48. Faus H, Haendler B (2008) Androgen receptor acetylation sites differentially regulate gene control. J Cell Biochem 104(2): 511-24.
49. Fu M, Liu M, Sauve AA, Jiao X, Zhang X, et al. (2006) Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol 26(21): 8122-35.
50. You M, Liang X, Ajmo JM, Ness GC (2008) Involvement of mammalian sirtuin 1 in the action of ethanol in the liver. Am J Physiol Gastrointest Liver Physiol 294(4): G892-8.
51. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M (2008) Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 295(4): G833-42.